Health Condition 1: L989- Disorder of the skin and subcutaneous tissue, unspecified
Conditions
Interventions
Intervention1: SKin spray device: Apply donor skin to raw wound using skin spray device just once at the time of enrolment for a time period enough to cut the donor skin into small segements
Control I
Sponsors
Kasturba Medical College Manipal
Eligibility
Inclusion criteria
Inclusion criteria: 1. Adults 18 years and above, any sex, willing to provide a written informed consent. [Women must be of no child-bearing potential or must have tested Negative for UPT] Female participants can be considered not of childbearing potential only if they are with current bilateral tubal ligation or occlusion, or post-hysterectomy, or post-bilateral ovariectomy, or post-menopause. 2. Patients who are hospitalized and in whom Split thickness skin graft is harvested 3. The participant/ Legally acceptable representative is willing to give written informed consent
Exclusion criteria
Exclusion criteria: 1. Patients who are critically ill 2. Documented skin disease at the time of enrollment as judged by the investigator 3. Treatment with immunosuppressants 4. Women who are pregnant or breast feeding 5. Inclusion in other ongoing study at present that would preclude the subject from participating in this study as judged by the investigator 6. Any other pathology that in the investigators opinion might interfere with the current study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| a.Spray area to the harvested donor area ratio on the donor site b.Area of epithelialization c.Percentage of epithelialization measured with imaging software in order to compare with the initial wound area. Timepoint: Days 5 7 and 10 | — |
Secondary
| Measure | Time frame |
|---|---|
| a. Incidence of infection/ Discharge b. Delay in healing due to complications c. Number of dressings d. Antiseptics, antibiotics and analgesics as well as skin-related medication doses required e. Adverse device effect and serious adverse device effect (Infection of the study site, Failure of the graft to grow, Pain and discomfort have already beenide ntified as anticipated effects in the Product Risk Management Record) Timepoint: Day 10;VAS Pain scoreTimepoint: Days 5 7 and 10 | — |
Countries
India
Contacts
Public ContactDr Jeffrey Pradeep Raj
Kasturba Medical College Manipal
Outcome results
None listed